MCK Stock Overview
Provides healthcare services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
WA
WarrenAI
Based on Analyst Price Targets
Leveraging AI And Decisive Partnerships Boosts Growth In Oncology And Biopharma, Outpacing Market Challenges
US$611.70
FV
17.6% undervalued intrinsic discount10.72%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 2 months agoauthor updated this narrative
McKesson Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$504.17 |
| 52 Week High | US$637.51 |
| 52 Week Low | US$417.65 |
| Beta | 0.44 |
| 11 Month Change | -7.92% |
| 3 Month Change | -14.10% |
| 1 Year Change | 19.82% |
| 33 Year Change | 148.69% |
| 5 Year Change | 251.26% |
| Change since IPO | 2,955.58% |
Recent News & Updates
Recent updates
McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22
McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus
Oct 08McKesson extends distribution partnership with CVS Health
Sep 29An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued
Sep 19McKesson to acquire Rx Savings Solutions in $875M deal
Sep 19Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD
Aug 15Shareholder Returns
| MCK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -10.1% | -1.0% | -4.4% |
| 1Y | 19.8% | 15.9% | 19.1% |
Return vs Industry: MCK exceeded the US Healthcare industry which returned 15.9% over the past year.
Return vs Market: MCK matched the US Market which returned 19.1% over the past year.
Price Volatility
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 4.8% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MCK's share price has been volatile over the past 3 months.
Volatility Over Time: MCK's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
McKesson Corporation Fundamentals Summary
| MCK fundamental statistics | |
|---|---|
| Market cap | US$65.38b |
| Earnings (TTM) | US$2.96b |
| Revenue (TTM) | US$313.75b |
22.1x
P/E Ratio0.2x
P/S RatioIs MCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCK income statement (TTM) | |
|---|---|
| Revenue | US$313.75b |
| Cost of Revenue | US$301.04b |
| Gross Profit | US$12.71b |
| Other Expenses | US$9.76b |
| Earnings | US$2.96b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.82 |
| Gross Margin | 4.05% |
| Net Profit Margin | 0.94% |
| Debt/Equity Ratio | -394.1% |
How did MCK perform over the long term?
See historical performance and comparison